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Abstract
Background:  Bioelectrical impedance analysis (BIA) is an easy-to-use, non-invasive, and
reproducible technique to evaluate changes in body composition and nutritional status. Phase angle,
determined by bioelectrical impedance analysis (BIA), detects changes in tissue electrical properties
and has been hypothesized to be a marker of malnutrition. Since malnutrition can be found in
patients with breast cancer, we investigated the prognostic role of phase angle in breast cancer.
Methods: We evaluated a case series of 259 histologically confirmed breast cancer patients
treated at Cancer Treatment Centers of America. Kaplan Meier method was used to calculate
survival. Cox proportional hazard models were constructed to evaluate the prognostic effect of
phase angle independent of stage at diagnosis and prior treatment history. Survival was calculated
as the time interval between the date of first patient visit to the hospital and the date of death from
any cause or date of last contact/last known to be alive.
Results: Of 259 patients, 81 were newly diagnosed at our hospital while 178 had received prior
treatment elsewhere. 56 had stage I disease at diagnosis, 110 had stage II, 46 had stage III and 34
had stage IV. The median age at diagnosis was 49 years (range 25 – 74 years). The median phase
angle score was 5.6 (range = 1.5 – 8.9). Patients with phase angle <= 5.6 had a median survival of
23.1 months (95% CI: 14.2 to 31.9; n = 129), while those > 5.6 had 49.9 months (95% CI: 35.6 to
77.8; n = 130); the difference being statistically significant (p = 0.031). Multivariate Cox modeling,
after adjusting for stage at diagnosis and prior treatment history found that every one unit increase
in phase angle score was associated with a relative risk of 0.82 (95% CI: 0.68 to 0.99, P = 0.041).
Stage at diagnosis (p = 0.006) and prior treatment history (p = 0.001) were also predictive of
survival independent of each other and phase angle.
Conclusion: This study demonstrates that BIA-derived phase angle is an independent prognostic
indicator in patients with breast cancer. Nutritional interventions targeted at improving phase angle
could potentially lead to an improved survival in patients with breast cancer.
Published: 27 August 2008
BMC Cancer 2008, 8:249 doi:10.1186/1471-2407-8-249
Received: 19 February 2008
Accepted: 27 August 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/249
© 2008 Gupta et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:249 http://www.biomedcentral.com/1471-2407/8/249
Page 2 of 7
(page number not for citation purposes)
Background
In the United States, breast cancer is the most common
non-skin cancer and the second leading cause of cancer-
related death in women [1].
Malnutrition is a frequent manifestation in patients with
advanced cancer and is a major contributor to morbidity
and mortality [2]. Malnutrition is characterized by
changes in cellular membrane integrity and alterations in
fluid balance [3]. As a result, measurement of body com-
position is an important component of overall nutritional
evaluation in cancer patients [4-6].
Several studies have investigated the relationship between
diet, physical activity, obesity and survival in breast cancer
[7-11]. A prospective study was performed on 1,490
women diagnosed and treated for early-stage breast cancer
between 1991 and 2000. In univariate analysis, reduced
mortality was weakly associated with higher vegetable-
fruit consumption, increased physical activity, and a body
mass index that was neither low weight nor obese [7].
Another study investigated the influence of diet, including
dietary fat (percentage energy), fiber, vegetable, and fruit
intakes, and micronutrients (folate, carotenoids, and vita-
min C) on overall survival in 516 postmenopausal
women diagnosed with breast cancer. In the multivariate
analysis, the hazard ratio of dying in the highest tertile
compared to the lowest tertile of total fat, fiber, vegetable,
and fruit was 3.12 (95% CI = 1.79–5.44), 0.48 (95% CI =
0.27–0.86), 0.57 (95% CI = 0.35–0.94), and 0.63 (95%
CI = 0.38–1.05), respectively (P <or= 0.05 for trend,
except for fruit intake) [9]. A review article summarized
the evidence from clinical and epidemiologic studies that
have examined the relationship between nutritional fac-
tors, survival, and recurrence after the diagnosis of breast
cancer. The article reported that overweight or obesity was
associated with poorer prognosis in the majority of the
studies that have examined this relationship. Treatment-
related weight gain also may influence disease-free sur-
vival, reduce quality of life, and increase risk for comorbid
conditions [11]. Clearly, much remains to be learned
about the role of nutritional factors in survival after the
diagnosis of breast cancer, especially with the advent of
novel techniques to assess nutritional status.
Historically, nutritional status has been evaluated by vari-
ous objective measures, including anthropometric (e.g.
weight change, arm muscle circumference, triceps skin-
fold thickness) and laboratory (serum albumin, transfer-
rin assays and nitrogen balance studies) measurements.
Anthropometric methods are not ideal in a clinical setting
because they are time-consuming and require well-trained
staff. Some of the objective measures such as serum albu-
min are likely to be influenced by many non-nutritional
factors [12-15]. Furthermore, some objective indicators
such as serum albumin have long half-lives, thus, assess-
ing changes in the nutritional status over a short period of
time is challenging. A less common tool to assess body
composition and nutritional status, called Bioelectrical
Impedance Analysis (BIA), can overcome some of these
challenges. BIA is an easy-to-use, non-invasive, and repro-
ducible technique to evaluate changes in body composi-
tion.
BIA has been validated for the assessment of body compo-
sition and nutritional status in a variety of patient popu-
lations including cancer [2,5,16-26]. BIA measures body
component resistance (R) and reactance (Xc) by recording
a voltage drop in applied current [27]. Resistance is the
restriction to the flow of an electric current, primarily
related to the amount of water present in the tissues. Reac-
tance is the resistive effect produced by the tissue inter-
faces and cell membranes [28]. Reactance causes the
current to lag behind the voltage creating a phase shift,
which is quantified geometrically as the angular transfor-
mation of the ratio of reactance to resistance, or the phase
angle [29].
Phase angle reflects the relative contributions of fluid
(resistance) and cellular membranes (reactance) of the
human body. By definition, phase angle is positively asso-
ciated with reactance and negatively associated with resist-
ance [29]. Lower phase angles suggest cell death or
decreased cell integrity, while higher phase angles suggest
large quantities of intact cell membranes [30]. Phase angle
has been found to be a prognostic marker in several clini-
cal conditions such as human immunodeficiency virus
infection, liver cirrhosis, chronic obstructive pulmonary
disease, hemodialysis, sepsis, lung cancer [30-35]. Previ-
ously, we had demonstrated the prognostic role of phase
angle in advanced colorectal and pancreatic cancer
[36,37]. The primary objective of this study, which builds
upon our prior research work in this area, was to evaluate
the association of BIA-derived phase angle with survival in
patients with breast cancer.
Methods
A retrospective chart review was performed on a consecu-
tive case series of 259 female breast cancer patients treated
at Cancer Treatment Centers of America (CTCA)® at Mid-
western Regional Medical Center (MRMC) between Janu-
ary 2001 and May 2006. The patients were identified from
the MRMC tumor registry. Only patients with a histologi-
cally confirmed diagnosis of breast cancer were included
in this study. The study was approved by the Institutional
Review Board at MRMC.
All patients underwent a baseline nutritional assessment,
which included laboratory measurements of serum albu-
min, prealbumin and transferrin, subjective global assess-BMC Cancer 2008, 8:249 http://www.biomedcentral.com/1471-2407/8/249
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ment (SGA), and BIA. BIA was performed by a registered
dietitian using a Bioelectrical Impedance Analyzer, Model
BIA-101Q: RJL Systems, Clinton Township, MI, USA. BIA
was conducted while patients were lying supine on a bed
or exam table, with legs apart and arms not touching the
torso. All evaluations were conducted on the patients'
right side using the four surface standard electrode (tetra
polar) technique on the hand and foot [23]. Resistance
(R) and reactance (Xc) were directly measured in Ohms at
50 Khz, 800 μA using RJL BIA. One assessment of resist-
ance (R) and reactance (Xc) was made. Phase angle was
calculated using the following equation: Phase Angle =
(Resistance/Reactance)*(180/π).
All data were analyzed using SPSS 11.5 (SPSS Inc., Chi-
cago, IL, USA). Patient survival was defined as the time
interval between date of first patient visit to the hospital
and date of death from any cause or date of last contact/
last known to be alive. The Kaplan-Meier or product-limit
method was used to calculate survival. The log rank test
statistic was used to evaluate the equality of survival dis-
tributions across different strata. A difference was consid-
ered to be statistically significant if the p value was less
than or equal to 0.05. Survival was also evaluated using
univariate and multivariate Cox regression analysis. Vari-
ables evaluated included phase angle, age at diagnosis,
prior treatment history and stage at diagnosis. For the pur-
pose of univariate analysis, phase angle measurements
were categorized using SPSS into 2 mutually exclusive
groups with median = 5.6 as the cut-off. For the purpose
of multivariate analyses, phase angle was treated as a con-
tinuous variable. Similarly, stage at diagnosis variable was
treated as a dichotomous variable with 2 categories – early
stage (stages I and II) and late stage (stages III and IV).
Results
At the time of this analysis (May 07), 85 patients had
expired and 174 were censored, as shown in Table 1. The
cut-off date for the follow-up for all participants was May
07. The median age at diagnosis was 49 years (range 25 –
74 years). The median phase angle score was 5.6 (range =
1.5 – 8.9). Phase angle was found to be non-normally dis-
tributed. Table 2 shows the univariate survival analysis of
different prognostic factors. Phase angle, tumor stage and
treatment history were found to be statistically signifi-
cantly associated with survival.
Figure 1 shows the survival curves for the two categories of
the phase angle. Patients with phase angle <= 5.6 had a
median survival of 23.1 months (95% CI: 14.2 to 31.9; n
= 129), while those > 5.6 had 49.9 months (95% CI: 35.6
to 77.8; n = 130); the difference being statistically signifi-
cant (p = 0.031).
Table 3 summarizes the results of multivariate Cox regres-
sion analyses. Multivariate Cox modeling, after adjusting
for stage at diagnosis and prior treatment history found
that every one unit increase in phase angle score was asso-
ciated with a relative risk of 0.82 (95% CI: 0.68 to 0.99, P
= 0.041). Stage at diagnosis (p = 0.006) and prior treat-
ment history (p = 0.001) were also predictive of survival
independent of each other and phase angle. Phase angle
was also used as a squared term in Cox regression due to
its non-linear association with mortality (Table 4).
Discussion
The current study was undertaken to investigate if BIA-
derived phase angle could predict survival in breast can-
cer.
This study demonstrated that phase angle is a strong pre-
dictor of survival in breast cancer after controlling for the
effects of stage at diagnosis and prior treatment history. A
similar study conducted in patients with advanced lung
cancer stratified the patient cohort by the mean phase
angle score of 4.5. Interestingly, patients with phase angle
scores less than or equal to 4.5 had a significantly shorter
survival than those with phase angle scores greater than
4.5 [38]. In our previous study in stage IV colorectal can-
cer patients, we found that phase angle above the median
cut-off of 5.6 was associated with better survival [37]. Sim-
ilarly, in stage IV pancreatic cancer, phase angle above the
median cut-off of 5 was associated with improved survival
[36].
This study adds to the growing body of evidence regarding
the clinical applications of BIA derived phase angle
beyond its use in body composition equations. Although
the biological meaning of phase angle is not well under-
Table 1: Patient characteristics
Characteristic Categories Number Percent (%)
Vital Status Expired 85 32.8
Censored1 174 67.2
Prior Treatment Progressive disease 178 68.7
History Newly diagnosed 81 31.3
Stage at Diagnosis Stage I 56 21.6
Stage II 110 42.5
Stage III 46 17.8
Stage IV 34 13.1
Missing 13 5.0





1 Patients who reached the end of their follow-up without 
experiencing death.
N = 259BMC Cancer 2008, 8:249 http://www.biomedcentral.com/1471-2407/8/249
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Table 2: Univariate Kaplan-Meier survival analysis
Variable Median survival in months Log-rank score P-value
Phase Angle
• <= 5.6 23.1 (14.2 to 31.9) 4.9 0.031
• >5.6 49.9 (35.6 to 77.8)
Tumor Stage
• Stage I and II 54.2 (35.3 to 83.2) 5.4 0.021
• Stage III and IV 22.9 (14.0 to 31.9)
Treatment History
• Newly diagnosed 54.6 (53.8 to 55.4) 50.2 0.0001
• Progressive disease 18.7 (14.8 to 22.5)
N = 259
Survival stratified by phase angle categories with cutoff of 5.6 Figure 1
Survival stratified by phase angle categories with cutoff of 5.6. Each drop in a probability curve indicates one or more 
events in that group. Vertical lines indicate censored patients, i.e., those who reached the end of their follow-up without expe-
riencing death.
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stood, it reflects not only body cell mass, but is also one
of the best indicators of cell membrane function, related
to the ratio between extracellular water and intracellular
water [28]. Schwenk et al. has hypothesized that phase
angle could possibly be interpreted as a global marker of
malnutrition in HIV infected patients [35]. In another
study conducted on HIV-infected patients, it was argued
that phase angle reflects the integrity of vital cell mem-
branes [33]. In patients with liver cirrhosis, phase angle
was speculated to be a marker of clinically relevant malnu-
trition characterized by both increased extracellular mass
and decreased body cellular mass [30]. In advanced lung
cancer, phase angle was speculated to be an indicator of
altered tissue electrical properties [38]. In spite of lack of
standardized cut-off values, phase angle seems to play an
important role as a marker of morbidity and mortality in
a wide range of disease conditions, with higher phase
angle reflecting a general indicator of wellness [28].
Limitations of this study relate to the BIA technique and
retrospective study design. This study, because of its retro-
spective nature, relies on data not primarily meant for
research. One potential limitation of the BIA approach for
estimating body composition is the reliance on regression
models, derived in restricted samples of human subjects,
which limits the usefulness of the derived model in other
patients who differ from the original sample in which the
model was developed [39,40]. However, in our study, we
looked at phase angle which does not depend on regres-
sion equations to be calculated, thereby eliminating a
large source of random error [3]. It has also been sug-
gested that the variability of direct bioimpedance meas-
ures (resistance, reactance, and phase angle) depends on
age, gender, and body mass characteristics of the study
population which could possibly limit the extrapolation
of the model [28,39,41]. A review article by Foster et al.
argued that although the correlation between whole-body
impedance measurements and body composition is
experimentally well established, the reason for the success
of the impedance technique is much less clear [42].
Some other reported limitations of using BIA for assess-
ment of body composition are hydration status and/or
major disturbances of water distribution, body position
during procedure, ambient air and skin temperatures,
recent physical activity, conductance of the examining
table, and food consumption [43]. Since the original
intent of the BIA in this study was to gather estimates of
body composition as part of a baseline nutritional assess-
ment in a clinical setting, not all of these factors could
realistically be controlled. Patients were free of visible
edema or ascites so there was control for obvious overhy-
dration. Body position was controlled for because all
patients were in the supine position in a bed or on an
exam table. Air temperature was within a controlled range
in our hospital setting. Physical activity was limited in
these patients due to the advanced nature of their disease.
Finally, food intake was not controlled for in this clinical
setting, which may have contributed to a small amount of
variability.
The cut-off point for phase angle in the present study was
generated so as to divide the patient population into 2
equal and mutually exclusive groups. The cut-off value of
phase angle in out study might differ from those in other
patient populations. Although our cut-off point was in
agreement with those reported by other studies
[30,35,38], there is a clear need to define threshold values
for phase angle as a nutritional assessment tool using
Receiver Operating Characteristic analysis based on large
prospective studies in advanced cancer. We also think that
restricting the analysis to newly diagnosed patients
(patients with no prior treatment history) would have
been more accurate, since it would have allowed for eval-
uation of true overall survival time, i.e. time from the date
of diagnosis to the date of death. However, doing so
Table 3: Multivariate Cox proportional hazard model (phase angle as a continuous variable)
Independent Variable Unit of increase RR1 95% CI P-value
Phase angle 1 degree 0.82 0.68, 0.99 0.041
Stage at Diagnosis Stage I and II as referent 1.9 1.2, 2.9 0.006
Treatment History Newly Diagnosed as referent 7.9 4.1, 15.5 0.001
Table 4: Multivariate Cox proportional hazard model (phase angle as a squared term)
Independent Variable Unit of increase RR1 95% CI P-value
Squared Phase angle 1 degree square 0.98 0.96, 1.001 0.06
Stage at Diagnosis Stage I and II as referent 1.9 1.2, 2.9 0.007
Treatment History Newly Diagnosed as referent 7.9 4.1, 15.2 0.001
1 Relative risk (Cox proportional hazard)
N = 259BMC Cancer 2008, 8:249 http://www.biomedcentral.com/1471-2407/8/249
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would have caused a significant reduction in the sample
size. In our study, the survival time was calculated from
the day of first visit at our hospital because the BIA meas-
urements were not available at the time of diagnosis for
previously treated patients. This limitation emphasizes
the need for conducting prospective studies, which have
nutritional information available since the date of diagno-
sis. No assessment of inter-rater reliability of the users of
BIA was made in this study. This bias, however, was min-
imized by restricting the use of BIA to well-trained dieti-
tians with an expertise in the use of this clinical technique.
Conclusion
In summary, our study has demonstrated the prognostic
significance of phase angle in breast cancer after control-
ling for the effects of stage at diagnosis and prior treat-
ment history.
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